Amphivena Closes $62 Million Series C Financing to Expand the Clinical Development of AMV564 into Solid Tumors and to Develop its T Cell Engagement Portfolio

VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.